ozekibart
Other
Evidence outlook · regulatory review
Conventional Chondrosarcoma: application under FDA review, decision date 2027-04-14
FDA accepts the ozekibart BLA in conventional chondrosarcoma (PDUFA goal date 14 April 2027) (2026-06-15). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.
ChonDRAgon (NCT04950075): This was a randomized, quadruple-masked Phase 2 trial with 206 participants. Its primary endpoint was met according to the sponsor's announcement of 2025-10-23. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ChonDRAgon NCT04950075 · Conventional Chondrosarcoma This was a randomized, quadruple-masked Phase 2 trial with 206 participants. Its primary endpoint was met according to the sponsor's announcement of 2025-10-23. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate. Registry: NCT04950075 | 2 | Progression-free survival per RECISTv1.1 by real time IRR comparing INBRX-109 and placebo (3 years) 2025-09-30 | Primary endpoint, progression-free survival vs placebo: stratified HR 0.479 (95% CI 0.33 to 0.68; p<0.0001), median 5.52 vs 2.66 months (ChonDRAgon, Inhibrx, 2025-10-23). | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Phase 1 (1)
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow ozekibart to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
December 2028 (1)
What to watch
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent